GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 196,500 shares, an increase of 5.1% from the January 15th total of 186,900 shares. Approximately 10.0% of the company’s shares are short sold. Based on an average daily trading volume, of 431,600 shares, the short-interest ratio is currently 0.5 days.

GT Biopharma Price Performance

NASDAQ GTBP opened at $2.14 on Tuesday. The company’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $2.48. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GTBP. Roth Mkm began coverage on shares of GT Biopharma in a report on Monday, December 2nd. They issued a “buy” rating and a $11.00 target price for the company. Roth Capital upgraded shares of GT Biopharma to a “strong-buy” rating in a report on Monday, December 2nd.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.